NCT01525407View on ClinicalTrials.gov

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

February 29, 2016

Conditions
Malignant Neoplasm
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo myeloablative allogeneic PBSC transplant

DRUG

Atorvastatin Calcium

Given PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo myeloablative allogeneic PBSC transplant

Trial Locations (3)

80907

Colorado Blood Cancer Institute, Denver

94305

Stanford University Hospitals and Clinics, Stanford

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01525407 - Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation | Biotech Hunter | Biotech Hunter